Novo Nordisk Stock Slips as Sales Grow Less Than Expected

Key TakeawaysAfter rising in premarket trading, Novo Nordisk's U.S.-listed shares fell after the market opened Wednesday as its third-quarter sales fell short of estimates despite continued growth form weight-loss drugs Ozempic and Wegovy.Sales rose 21% from the same time last year, but analysts had expected them to rise a bit higher.The Danish drugmaker also narrowed its full-year projections for revenue and operating profit. After rising in premarket trading, Novo Nordisk's (NVO) U.S.-listed shares fell a ...